Maintenance treatment in multiple myeloma.
Harousseau
J L
JL
Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000473:pathology / Q000628:therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction / Q000379:methods; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide